Literature DB >> 31125735

Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial.

Hilary A Robbins1, Hormuzd A Katki2, Li C Cheung2, Rebecca Landy2, Christine D Berg2.   

Abstract

BACKGROUND: In the National Lung Screening Trial (NLST), screen-detected cancers that would not have been identified by the Lung Computed Tomographic Screening Reporting and Data System (Lung-RADS) nodule management guidelines were frequently ground-glass opacities (GGOs). Lung-RADS suggests that GGOs with diameter less than 20 mm return for annual screening, and GGOs greater than or equal to 20 mm receive 6-month follow-up. We examined whether this 20-mm threshold gives consistent management of GGOs compared with solid nodules.
METHODS: First, we calculated diameter-specific malignancy probabilities for GGOs and solid nodules in the NLST. Using the solid-nodule malignancy risks as benchmarks, we suggested risk-based management categories for GGOs based on their probability of malignancy. Second, we compared lung-cancer mortality between GGOs and solid nodules in the same risk-based category.
RESULTS: Using the Lung-RADS v1.0 classifications, malignancy probability is higher for GGOs than solid nodules within the same category. A risk-based classification of GGOs would assign annual screening for GGOs 4 to 5 mm (0.4% malignancy risk); 6-month follow-up for GGOs 6 to 7 mm (1.1%), 8 to 14 mm (3.0%), and 15 to 19 mm (5.2%); and 3-month follow-up for greater than or equal to 20 mm (10.9%). This reclassification would have assigned similarly fatal cancers to 3-month follow-up (hazard ratio = 2.0 for lung-cancer death in GGOs versus solid-nodule cancers, 95% confidence interval: 0.4-8.7), but for 6-month follow-up, mortality was lower in GGO cancers (hazard ratio = 0.18, 95% confidence interval: 0.05-0.67).
CONCLUSIONS: If Lung-RADS categories for GGOs were based on malignancy probability, then 6- to 19-mm GGOs would receive 6-month follow-up and greater than or equal to 20-mm GGOs would receive 3-month follow-up. Such risk-based management for GGOs could improve the sensitivity of Lung-RADS, especially for large GGO cancers. However, small GGO cancers were less aggressive than their solid-nodule counterparts.
Copyright © 2019 World Health Organization. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomographic screening; Ground-glass opacities; Lung Computed Tomographic Screening Reporting and Data System; Lung cancer screening; Malignancy probability; Nodule classification; Risk-based screening

Mesh:

Year:  2019        PMID: 31125735      PMCID: PMC6909540          DOI: 10.1016/j.jtho.2019.05.012

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

1.  Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

Authors:  Paul F Pinsky; David S Gierada; William Black; Reginald Munden; Hrudaya Nath; Denise Aberle; Ella Kazerooni
Journal:  Ann Intern Med       Date:  2015-04-07       Impact factor: 25.391

2.  The relationship of cancer characteristics and patient outcome with time to lung cancer diagnosis after an abnormal screening CT.

Authors:  Sushilkumar K Sonavane; Paul Pinsky; Jubal Watts; David S Gierada; Reginald Munden; Satinder P Singh; Hrudaya Nath
Journal:  Eur Radiol       Date:  2017-06-14       Impact factor: 5.315

3.  Solitary Pure Ground-Glass Nodules 5 mm or Smaller: Frequency of Growth.

Authors:  Ryutaro Kakinuma; Yukio Muramatsu; Masahiko Kusumoto; Takaaki Tsuchida; Koji Tsuta; Akiko Miyagi Maeshima; Hisao Asamura; Noriyuki Moriyama
Journal:  Radiology       Date:  2015-04-23       Impact factor: 11.105

4.  Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening.

Authors:  Daiwei Han; Marjolein A Heuvelmans; Rozemarijn Vliegenthart; Mieneke Rook; Monique D Dorrius; Gonda J de Jonge; Joan E Walter; Peter M A van Ooijen; Harry J de Koning; Matthijs Oudkerk
Journal:  Br J Radiol       Date:  2017-11-08       Impact factor: 3.039

5.  Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Joan E Walter; Rozemarijn Vliegenthart; Peter M A van Ooijen; Geertruida H De Bock; Harry J de Koning; Matthijs Oudkerk
Journal:  Thorax       Date:  2017-10-22       Impact factor: 9.139

Review 6.  Lung-RADS: Pushing the Limits.

Authors:  Maria D Martin; Jeffrey P Kanne; Lynn S Broderick; Ella A Kazerooni; Cristopher A Meyer
Journal:  Radiographics       Date:  2017-10-20       Impact factor: 5.333

7.  Probability of cancer in pulmonary nodules detected on first screening CT.

Authors:  Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

8.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

9.  Subcentimeter lung nodules stable for 2 years at LDCT: long-term follow-up using volumetry.

Authors:  Kyung Eun Shin; Kyung Soo Lee; Chin A Yi; Myung Jin Chung; Myung-Hee Shin; Yoon-Ho Choi
Journal:  Respirology       Date:  2014-06-17       Impact factor: 6.424

10.  Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.

Authors:  Sarah J van Riel; Francesco Ciompi; Colin Jacobs; Mathilde M Winkler Wille; Ernst Th Scholten; Matiullah Naqibullah; Stephen Lam; Mathias Prokop; Cornelia Schaefer-Prokop; Bram van Ginneken
Journal:  Eur Radiol       Date:  2017-03-14       Impact factor: 5.315

View more
  6 in total

1.  A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.

Authors:  Zhenyu Zhao; Wei Yin; Xiong Peng; Qidong Cai; Boxue He; Shuai Shi; Weilin Peng; Guangxu Tu; Yunping Li; Dateng Li; Yongguang Tao; Muyun Peng; Xiang Wang; Fenglei Yu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

2.  [Preliminary Recommendations for Lung Surgery during 2019 Novel Coronavirus Disease (COVID-19) Epidemic Period].

Authors:  Xin Li; Minghui Liu; Qingchun Zhao; Renwang Liu; Hongbing Zhang; Ming Dong; Song Xu; Honglin Zhao; Sen Wei; Zuoqing Song; Gang Chen; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-02-20

3.  Subsolid pulmonary nodules: Controversy and perspective.

Authors:  Mark M Hammer; Hiroto Hatabu
Journal:  Eur J Radiol Open       Date:  2020-09-04

4.  Preliminary recommendations for lung surgery during COVID-19 epidemic period.

Authors:  Xin Li; Minghui Liu; Qingchun Zhao; Renwang Liu; Hongbing Zhang; Ming Dong; Song Xu; Jinghao Liu; Honglin Zhao; Sen Wei; Zuoqing Song; Gang Chen; Jun Chen
Journal:  Thorac Cancer       Date:  2020-04-14       Impact factor: 3.500

5.  Combination of electromagnetic navigation bronchoscopy-guided microwave ablation and thoracoscopic resection: An alternative for treatment of multiple pulmonary nodules.

Authors:  Ning Jiang; Liming Zhang; Yingtao Hao; Xiaolin Wu; Yunpeng Zhao; Bo Cong; Chuanliang Peng
Journal:  Thorac Cancer       Date:  2020-04-14       Impact factor: 3.500

6.  Recommendations for acting in elective and urgent thoracic surgery during SARS-CoV-2 pandemic. Spanish Society of Thoracic Surgery.

Authors:  José R Jarabo; Néstor Martínez; Alberto Cabañero; Sergi Call; José L Campo-Cañaveral; Ángel Cilleruelo; Usue Caballero; Andrés Obeso; José L Recuero; Sebastián Sevilla; Florentino Hernando
Journal:  Cir Esp (Engl Ed)       Date:  2020-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.